Wasatch Advisors LP Buys 2,287 Shares of Artivion, Inc. (NYSE:AORT)

Wasatch Advisors LP boosted its stake in Artivion, Inc. (NYSE:AORT) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 519,019 shares of the company’s stock after purchasing an additional 2,287 shares during the period. Wasatch Advisors LP’s holdings in Artivion were worth $9,280,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AORT. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Artivion by 25.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock valued at $186,000 after acquiring an additional 2,108 shares during the last quarter. New York State Common Retirement Fund raised its stake in shares of Artivion by 25.0% during the third quarter. New York State Common Retirement Fund now owns 15,009 shares of the company’s stock valued at $228,000 after acquiring an additional 2,999 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Artivion by 7.8% during the fourth quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock valued at $239,000 after acquiring an additional 968 shares during the last quarter. Dark Forest Capital Management LP raised its stake in shares of Artivion by 30.8% during the third quarter. Dark Forest Capital Management LP now owns 18,566 shares of the company’s stock valued at $281,000 after acquiring an additional 4,374 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Artivion during the third quarter valued at $290,000. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

AORT has been the subject of several analyst reports. Needham & Company LLC raised their price target on shares of Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Stifel Nicolaus increased their price objective on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $20.39, for a total value of $44,511.37. Following the completion of the sale, the senior vice president now directly owns 83,296 shares in the company, valued at $1,698,405.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Artivion news, VP Andrew M. Green sold 1,462 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $20.00, for a total value of $29,240.00. Following the completion of the sale, the vice president now directly owns 41,121 shares in the company, valued at $822,420. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Marshall S. Stanton sold 2,183 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total transaction of $44,511.37. Following the completion of the sale, the senior vice president now owns 83,296 shares of the company’s stock, valued at $1,698,405.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,624 shares of company stock worth $97,042. 8.10% of the stock is currently owned by company insiders.

Artivion Trading Up 0.8 %

AORT opened at $23.46 on Wednesday. Artivion, Inc. has a twelve month low of $12.16 and a twelve month high of $25.51. The company has a quick ratio of 4.26, a current ratio of 6.04 and a debt-to-equity ratio of 1.07. The company has a fifty day moving average of $22.20 and a 200-day moving average of $19.83. The stock has a market cap of $978.28 million, a PE ratio of -97.75 and a beta of 1.72.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.04. Artivion had a negative net margin of 2.61% and a positive return on equity of 3.64%. The company had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. On average, sell-side analysts predict that Artivion, Inc. will post 0.24 EPS for the current year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.